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Background and Aims. The role of capsule endoscopy (CE) in the <50 years of age patients with iron deficiency anaemia (IDA)
remains unclear. We aim to assess its utility in this cohort.Methods. All patients referred for CE for recurrent IDA were included
retrospectively. Patients were divided into Group 1 (<50 years) and Group 2 (≥50 years). Results. There were 971 patients with
recurrent IDA and 28% belonged to Group 1. The mean age was 40 years in this group with a DY of 28% (𝑛 = 76). Significant
diagnoses included erosions and ulcers (26%; 𝑛 = 71), small bowel (SB) angioectasia (AE) (10%; 𝑛 = 27), SB tumours (3%; 𝑛 = 7),
Crohn’s disease (3%; 𝑛 = 7), SB bowel strictures (1%; 𝑛 = 3), and SB varices (1%; 𝑛 = 2). On logistic regression, the presence of
diabetes (𝑃 = 0.02) and the use of warfarin (𝑃 = 0.049) was associated with increased DY. The DY in Group 2 was 38% which
was significantly higher than in Group 1 (𝑃 = 0.02). While SB tumours were equally common in both groups, AE was commoner
in Group 2 (𝑃 < 0.001). Conclusion. A significant proportion of patients <50 years are referred for CE. Although the DY is lower
compared to those≥50 years, significant pathology is found in this age group. CE is advisable in patients<50 years oldwith recurrent
IDA and negative bidirectional endoscopies.
1. Introduction
Iron deficiency anaemia (IDA) still remains a common cause
for referral to a gastroenterologist (up to 13%) and is often
caused by chronic occult gastrointestinal bleeding [1, 2].
In patients where bidirectional endoscopy has been normal
and the IDA persists, investigating the small bowel (SB) is
warranted. It has been shown that, in patients with IDA, 30%
of patients will have normal bidirectional endoscopies [3]. In
view of this, both the American Gastroenterological Asso-
ciation (AGA) and the British Society of Gastroenterology
(BSG) have recommended SB investigation in particular to
detect lesions such as SB angioectasia (AE), Crohn’s disease,
and neoplasia [2, 4].
In 2001, the introduction of small bowel capsule
endoscopy (SBCE) into clinical practice opened new doors
in the investigation of obscure gastrointestinal bleeding
(OGIB) where the cause had not yet been identified by
esophagogastroduodenoscopy (OGD) and colonoscopy [5].
Today, it is the first line investigative tool for suspected SB
bleeding. The DY for SBCE ranges from 34% to 92% for
OGIB [6]. In anaemia exclusively, the DY is between 57%
and 78% [7, 8] and, in those over 70 years of age, AE is the
commonest cause of OGIB (30–40%) [9, 10]. Whilst there
are many studies investigating the use of CE in OGIB, there
is a paucity of studies looking specifically at the use of CE for
the sole indication of IDA. The literature on the use of CE in
patients < 50 years is also very limited [11].
The purpose of our study was to evaluate the utility of
CE in patients under the age of 50 years presenting with
recurrent IDA to a single tertiary institution in the United
Kingdom. We study clinical parameters that may predict
a higher DY and factors that had a subsequent impact on
patient management.
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Table 1: Distribution of all the findings on capsule endoscopy in patients <50 and ≥50 years of age with recurrent iron deficiency anaemia.
All CE findings Group 1 (𝑛 = 275) (%) Group 2 (𝑛 = 696) (%) 𝑃 value (95% CI; odds ratio)
SB ulcers and erosions 71 (26) 174 (25) 0.815 (0.8 to 1.4; 1.0)
SBAE 27 (10) 198 (28) <0.0001 (0.2 to 0.4; 0.3)
SB tumour 7 (3) 9 (1) 0.177 (0.3 to 5.4; 2.0)
SB Crohn’s disease 7 (3) 10 (1) 0.245 (0.7 to 4.7; 1.8)
Unspecified blood in the SB 6 (2) 37 (5) 0.038 (0.2 to 1.0; 0.4)
SB strictures 3 (1) 8 (1) 0.934 (0.3 to 3.6; 1.0)
SB varices 2 (1) 3 (0.4) 0.568 (0.3 to 10.2; 1.7)
Others SB findings (polyps, diverticulum,
dieulafoy, endometriosis, and celiac) 6 (2) 23 (3) 0.353 (0.3 to 1.6; 0.7)
UGIT erosions and ulcers 6 (2) 46 (7) 0.008 (0.1 to 0.7; 0.3)
Unspecified blood in the UGIT 3 (1) 23 (3) 0.066 (0.1 to 1.1; 0.3)
GAVE 2 (1) 21 (3) 0.051 (0.1 to 1.0; 0.2)
Other UGIT findings (portal
hypertensive gastropathy, varices, AE,
tumour, and UGIT polyps)
8 (3) 31 (5) 0.273 (0.3 to 1.4; 0.6)
Colorectal lesions 4 (2) 16 (2) 0.404 (0.2 to 1.9; 0.6)
CE: capsule endoscopy; IDA: iron deficiency anaemia; 95% CI: 95% confidence interval; SB: small bowel; AE: angioectasia; UGIT: upper gastrointestinal tract;
GAVE: gastric antral vascular ectasia.
2. Methods and Materials
2.1. Patients. All patients routinely referred for SBCE from
June 2002 to November 2012 for investigation of recurrent
IDA were included in this study. In the Sheffield Teaching
Hospitals NHS Trust and its referring hospitals, haemoglobin
concentrations below 13 g/dL in men and below 11 g/dL in
women are references used to define anaemia. Prior to refer-
ral for CE, all patients had undergone upper and lower gas-
trointestinal investigation with a negative DY either locally
(Sheffield Teaching Hospitals NHS Trust) or at the primary
referring hospital. This study was part of the small bowel
endoscopy study approved by the North Sheffield Ethics
Committee (07/2308/13). Data was collected retrospectively
on age, sex, indication, comorbidity, SBCEfindings,DY,man-
agement change, and subsequent procedures undertaken.
Significant findings on SBCE, which were deemed to be the
cause of the patients clinical presentation only, were included
in the diagnostic yield. Data was also collected specifically
on the use of nonsteroidal anti-inflammatory (NSAIDS),
warfarin, and blood transfusions.
2.2. Capsule Endoscopy. With patient consent, SBCE (Pill-
cam, Given Imaging, Yokneam Illit, Israel) was performed
in patients with recurrent IDA. The procedure involved
an overnight fast for 12 h after ingestion of two sachets of
polyethylene glycol solution (Kleen-Prep; Norgine, Middle-
sex, UK). The capsule was ingested with water and 80mg
simethicone (Infacol, Forest Laboratories, Kent,UK) anddata
subsequently downloaded onto the computer workstation as
per standard protocol [5]. All videos were analysed by either
experienced consultant gastroenterologist (RS and MEM) or
experienced advanced nurse practitioner (KD).
2.3. Statistical Analysis. The data were analysed using SPSS
version 18 (SPSS Inc., Chicago, IL, USA). Regression analysis
was carried out to determine which clinical factors predicted
diagnosis andmanagement change.A𝑃 value of less than 0.05
was considered statistically significant.
3. Results
3.1. Study Population. A total of 1324 patients were referred
for SBCE for investigation of obscure gastrointestinal bleed-
ing (OGIB).All patients had undergone both upper and lower
gastrointestinal investigations (at times, multiple) without a
DY. Of the 1324 patients, 73% (𝑛 = 971) were referred solely
with recurrent IDA while the remaining were referred with
overt bleeding (OB) (𝑛 = 353). Those with recurrent IDA
were then segregated into 2 groups based on age. Group 1 was
populated with patients <50 years of age while Group 2 was
populated with those ≥50 years of age.The cumulative DY for
patients with recurrent IDA in our study was 66%.
3.2. Group 1. Group 1 comprised 28% (𝑛 = 275) of the
aforementioned 971 patients. The mean age in Group 1 was
40 years, with the age ranging from 17 to 49 years with 61%
(𝑛 = 168) of patients being female. The DY in Group 1 was
28% (𝑛 = 76) with no difference between the sexes. All
significant diagnoses found in this age group are tabulated
in Table 1. Interestingly, 6 out of 7 SB tumours were found
in females. On logistic regression, the presence of diabetes
mellitus (𝑃 = 0.02) and the use of warfarin (𝑃 = 0.049) were
associated with increased DY. Management was altered in
75% (𝑛 = 57) of patients with aDYonCE. Further procedures
undertaken locally in patients with a management change
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Table 2: Distribution of anticoagulation and transfusions in the <50 and ≥50 years of age patients.
Medication Group 1 (𝑛 = 275) (%) Group 2 (𝑛 = 696) (%) 𝑃 value (95% CI; odds ratio)
Warfarin 5 (2) 74 (11) <0.001 (0.1 to 0.4; 0.2)
Nonsteroidal anti-inflammatories 14 (5) 63 (9) 0.042 (0.3 to 1.0; 0.5)
Transfusion dependent 8 (3) 52 (8) 0.010 (0.2 to 0.8; 0.4)
Previous transfusion 6 (2) 57 (8) 0.002 (0.1 to 0.6; 0.3)
included double balloon enteroscopy (DBE) (𝑛 = 11), push
enteroscopy (PE) (𝑛 = 2), repeat OGD (𝑛 = 2), and surgery
(𝑛 = 2). On logistic regression, the only clinical factors that
influenced a management change were SBAE (𝑃 = 0.02).
3.3. Group 2. Group 2 was made up of 72% (𝑛 = 696) of the
aforementioned 971 patients.Themean age was 68 years with
the age ranging from 50 to 92 years with 58% (𝑛 = 407) of
patients being female. The DY was 38% (𝑛 = 267) with no
difference between the sexes. Significant diagnoses found in
this age group are tabulated in Table 1. On logistic regression,
the presence of haematological disease (𝑃 = 0.02), chronic
renal disease (𝑃 = 0.03), and chronic liver disease (𝑃 = 0.04)
and being transfusion dependent (𝑃 = 0.049) were associated
with increasedDY.Management was altered in 72% (𝑛 = 191)
of patients with a DY on CE. Further procedures undertaken
locally in patients with a management change included DBE
(𝑛 = 28), PE (𝑛 = 20), repeat OGD (𝑛 = 16), colonoscopy
(𝑛 = 8), and surgery (𝑛 = 7) with 17% (𝑛 = 32) of patients
receiving APC therapy. On logistic regression, clinical factors
that were associated with a management change included the
presence of a comorbidity (𝑃 = 0.001) and SBAE (𝑃 < 0.001)
and being transfusion dependent (𝑃 = 0.04).
3.4. Comparisons between the Two Groups. On group com-
parison, DY was significantly higher in Group 2 (age ≥ 50
years) (𝑃 = 0.002) (95% CI = 1.2 to 2.2; odds ratio =
1.6) than in Group 1. There was no significant difference
in management change in patients with a DY (𝑃 = 0.55)
or total number of procedures undertaken locally, although
significantly more patients required APC therapy in Group
2 (𝑃 = 0.025) (95% CI = 1.3 to 75.5; odds ratio = 10.1).
SB erosions and ulcers (26%; 𝑛 = 71) were the commonest
finding in Group 1 while SBAE (28%; 𝑛 = 198) was in Group
2. In addition, Group 2 had significantly more comorbidities.
There was also significantly more patients on NSAIDS (𝑃 =
0.041) and warfarin (𝑃 = 0.001) as well as being transfusion
dependent (𝑃 = 0.01) and having had a previous transfusion
(𝑃 = 0.001) in Group 2 as tabulated in Table 2.
4. Discussion
The purpose of this study was to establish the importance
of CE in the investigation of younger patients with recur-
rent IDA of which there is limited data. Recent work by
Koulaouzidis et al. has been encouraging in trying to address
this shortcoming. With a DY of 25% for sinister/significant
lesions in the ≤40 years of age patients, they highlight the
importance of prioritising the young patient when investi-
gating IDA with CE [11]. Their study however still had a
relatively small sample size (𝑛 = 221). Our study builds on
their findings with a much larger sample size (𝑛 = 971), is
of an unselective nature, and is representative of CE findings
in routine practice. In our study, we have demonstrated that
the DY in patients <50 years was 28%. Significant pathology
identified in this group included SB tumours, ulcers, and AE.
In the <50 years of age patients, SBAE is the second
commonest finding after erosions and ulcers. It is found in
10% of the <50 years of age cohort and in 28% of the ≥50 year
of age cohort. Although SBAE is a disease primarily inflicting
the elderly, we found that SBAE also impacts as a factor in
management change in both the <50 years of age patients and
the ≥50 years of age patients.
SB tumours were found in 1.7% of our cohort with
recurrent IDA. This is slightly lower than that of previously
published work of 3.9% to 8.8% [8, 12, 13]. This result may
be a reflection of CE being routinely performed in patients
with recurrent IDA as compared to the stringent criteria set
in other studies. In our <50 years of age patients cohort, SB
tumours were found in 3% of patients which is similar to
findings by Koulaouzidis et al. [11]. In addition, SB tumours
weremore common in females in the<50 years of age patients
cohort.
In this study, we found that the DY of 66% in all
patients with recurrent IDA is in keeping with DY of recent
published work [8, 11, 12, 14–17]. We also found that diabetes
mellitus and warfarin influenced the DY in the <50 years
of age patients, whilst it was haematological disease, chronic
renal failure, and chronic liver disease and being transfusion
dependent that influencedDY in the≥50 years of age patients.
This is as predicted and partly explained by commonality
of pathology found in these age groups. In addition, other
investigators [11] including our previous work [18] have also
shown that transfusions, warfarin usage, and chronic liver
disease influenced DY.
This study also highlights a significant number of UGIT
findings in patients undergoing CE for recurrent IDA. There
has been similar reports in the literature, highlighting the
importance of meticulous upper and lower gastrointestinal
endoscopic examination [19, 20].
Limitations of this study included its retrospective nature,
all referrals made were taken at face value, and we did not
revisit the history to scrutinise any previous investigation
undertaken. In addition, we did not have the menopausal
status for all the females<50 years of age and our study lacked
the long term follow-up data on patients which would have
helped to strengthen this study. A further limitation was that
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there were also three reporters for all the SBCE included in
this study (RS, MEM, and KD). However, we have previously
demonstrated that our experienced nurse reader is equally
competent as a consultant gastroenterologist in the detection
of small bowel pathology and in providing a final SBCE report
[21].
5. Conclusion
A significant proportion of patients <50 years of age with
recurrent IDA were referred for CE. Although the DY is
lower compared to those over 50 years, significant pathology
is found in this age group. CE is advisable in patients <50
years of age with recurrent IDA and negative bidirectional
endoscopies.
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